American Society of Hirudotherapy

Hirudin--the long and stony way from an anticoagulant peptide in the saliva of medicinal leech to a recombinant drug and beyond. A historical piece

Research article published in Thrombosis and haemostasis (2007)

Last Updated: March 18, 2026Reviewed by: ASH Editorial Board
Research article — evidence reviewArticle reference
Drug DevelopmentSalivary PharmacologyClinical TrialsGenomics & ProteomicsNowak G, Schrör K · Thrombosis and haemostasis, 2007

Summary

Hirudin--the long and stony way from an anticoagulant peptide in the saliva of medicinal leech to a recombinant drug and beyond. A historical piece.

Why This Matters for Hirudotherapy

Relevant to the development and clinical application of leech-derived pharmaceutical compounds.

Citation

Hirudin--the long and stony way from an anticoagulant peptide in the saliva of medicinal leech to a recombinant drug and beyond. A historical piece.

Nowak G, Schrör K · Thrombosis and haemostasis, 2007

DOI

Added to ASH library: March 18, 2026 · Site last updated: March 18, 2026

This website provides educational information and does not constitute medical advice, diagnosis, or treatment recommendations. Medicinal leech therapy carries clinically meaningful risks and should be performed only by qualified clinicians under institutionally approved protocols. FDA 510(k) clearance for medicinal leeches is limited to specific indications; investigational and off-label discussions are labeled accordingly. For patient-specific guidance, consult a qualified healthcare provider.

Hirudin--the long and stony way from an anticoagulant peptide in the saliva of medicinal leech to a recombinant drug and beyond. A historical piece | ASH